2016;6(4):446-459. P824; Abstract A4313]. Analysis of a Composite Endpoint of Exacerbation and Early Study Treatment Withdrawal in Symptomatic Patients With COPD Free of Inhaled Corticosteroids: A Post Hoc Analysis of the EMAX Trial. Abstract Publication No. Cho E-Y, Cho J-E, Jang S-H, et al. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. Prevalence, Regional Distribution, and Trends of Antimicrobial Resistance Among Female Outpatients With Urine Klebsiella pneumoniae Isolates: A Multicenter Evaluation. A Population Study. Soler X, Siddall J, Small M, et al. [Abstract/Poster No. POSTER: A Retrospective Database Analysis of Treatment Pathways in US Medicare Patients with Multiple Myeloma and Prior Exposure to Daratumumab, an Immunomodulatory Agent, and a Proteasome Inhibitor, 5. 2017;276(1):97-111. Cancer Discov. POSTER: Immune-Related Endpoints in Patients with Advanced or Recurrent Endometrial Cancer Treated with Dostarlimab in the GARNET Study, 4. POSTER: Real-World Patterns and Predictors of First-Line Maintenance Use Among Patients with Newly Diagnosed Advanced Ovarian Cancer: Is There an Opportunity for Change? Curr Opin Pharmacol. 7. [Poster No. Kerwin EM, Bjermer L, Maltais F, et al. Additionally, Medical Affairs typically operates an information center to . 2015;23:82-91. P1454. 1. CAPTAIN: Effects of age as a continuous variable on asthma control. Singh AK, et al. This information does not take the place of talking with your doctor. POSTER: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment. Real-World Treatment Patterns Following Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients with Commercial or Medicare Insurance in the U.S. Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annualized Moderate and Severe Exacerbations. Real-World Impact of Triple Therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control among Patients with Asthma in the US. Review the package insert for important safety information. Stark A-K, Sriskantharjah S, Hessel EM, Okkenhaug K. PI3K inhibitors in inflammation, autoimmunity and cancer. P.O. Report an Adverse Event or Product Quality Complaint: 1-877-782-6966. [Abstract/Presentation No. Patient Perceptions of Treatment Success in Uncomplicated Urinary Tract Infection. Chupp G, Lee JK, Liu MC, et al. Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. This article outlines the aspects of Medical Affairs strategy and launch excellence specific to supporting the development and launch of treatments targeting rare diseases, providing a roadmap for MA teams and organizations undertaking this planning. 5. Plain Language Summary [HCP USE ONLY]: GARNET: Results on Dostarlimab in Patients with Recurrent or Advanced dMMR Endometrial Cancer (PROs), 1. A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study, 6. Sci Transl Med. NY-ESO-1?specific TCR?engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. 11. GSK3174998 is a humanized immunoglobulin 1 (IgG1) OX40 agonist antibody that can enhance the proliferation and survival of CD4+ and CD8+ T cells and deplete tumor-infiltrating regulatory T cells via antibody-dependent cell cytotoxicity or phagocytosis. Genmab makes no representation regarding the accuracy of the information on this site. NL8095.75.000.B.01, 777 Scudders Mill Road Assessment of Asthma Control in Respiratory Specialist Offices in the US. 2. 1. 2. 710; Abstract A1825]. about disease states including Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa. Welcome to AbbVie U.S. Medical Affairs This site is intended for U.S. Healthcare Professionals only. GSK3745417 is a synthetic STING agonist that is being investigated as a monotherapy and in combination with pembrolizumab in relapsed/refractory solid tumors. Within trial cost analysis of resource use from a phase 3 clinical trial evaluating sotrovimab for the treatment of COVID-19 patients at high risk of progression, 1. Singh AK, et al. PUBLICATION ONLY: Study Design of A Global Molecular Disease Characterization Initiative (MDCI) in Oncology Clinical Trials, 1. Nasal Polyp Symptoms: How Well Do Physicians Know Their Patients? Characteristics and Inpatient Outcomes of Hospitalized Patients with COVID-19 ? 2. 1. Once-Daily Single-Inhaler Versus Twice-Daily Multiple-Inhaler Triple Therapy: Two Replicate Trials in Patients With Chronic Obstructive Pulmonary Disease (COPD). POSTER: Treatment Patterns Among Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Second- and Third-Line Therapy in a Medicare Population, 2. Marketing & Communications. GSK is committed to monitoring the safety of our products and we encourage you or your health care provider to report any side effect or suspected overdose to GSK at 888-825-5249. Bell CF, et al. 8. CAPTAIN study: Effects of baseline IgE levels on triple therapy response in inadequately controlled asthma. ORAL PRESENTATION: Shapiro A, et al. Preliminary Safety, Efficacy, and Pharmacokinetic/Pharmacodynamic Characterization from GARNET, a Phase 1/2 Clinical Trial of the Anti PD 1 Monoclonal Antibody, Dostarlimab, in Patients with Recurrent or Advanced MSI H and MSS Endometrial Cancer (EC), For a copy of a poster please call 1-877-475-6448, 1. Seasonal Efficacy of Mepolizumab in Patients With Severe Eosinophilic Asthma ? Elaborating the Mechanism of PARP Synthetic Lethality in ATM Loss, 2. P0017. P786; Abstract A5624]. Poster No. Modeling of short-acting beta agonist (SABA) use: effect of symptom control in patients with moderate-severe asthma requiring rescue medication. POSTER: MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC), 7. [Poster No. Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: A TWiST analysis of the ENGOT OV16/NOVA trial, 2. PO2409, 3. POSTER: First-line Maintenance Among Advanced Ovarian Cancer Patients in The US Oncology Network: A Real-world Retrospective Cohort Study, 9. Brain Metastases in Primary Ovarian Cancer: Real-world Data, 1. POSTER: Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab (IGCS ENCORE), 11. CAPTAIN Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, a Pre-specified Subgroup Analysis. The Potential for Reducing Opioid and Analgesic Prescriptions via Herpes Zoster Vaccination, 8. Sponsoring education programs for healthcare practitioners. The information contained herein is provided for educational purposes only and is not intended to replace 2. signaling and HMGA2, a potential biomarker for bintrafusp alfa in triple negative breast cancer, 3. POSTER: Marijam A, et al. 10. Efficacy of Belimumab Across Multiple Organ Domains in Systemic Lupus Erythematosus: Results of a Large Integrated Analysis, 2. Comparative Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis. The Impact of Comorbid Nasal Polyps on Real-World Mepolizumab Effectiveness in Patients with Severe Asthma: Results from the REALITI-A Study. 1. My Medical Affairs (MyMA)provides you with one central place to keep up to date with all the upcoming events relevant to your medical affairs interests, from a plethora of organizations around the globe. Plain Language Summary [HCP USE ONLY]: ENGOT-EN6/GOG-3031/NSGO-RUBY: A phase 3, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC), 4. Real-World Treatment Patterns Following Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients with Commercial or Medicare Insurance in the U.S. 5. [Oral presentation available here; Abstract A4212]. Demographics and Characteristics of Patients Who Initiate Biologics for Asthma. 2. 5. POSTER: RSVPreF3 OA Candidate Vaccine Immunogenicity Presentation. AbbVie is not responsible for the contents of any such site or any further links from such site. ORAL FEATURED POSTER: Phase 2 OVARIO Study of Niraparib + Bevacizumab Therapy in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy With Bevacizumab, 6. Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. POSTER: Niraparib Exposure-Response Relationship in Patients (pts) with Newly Diagnosed Advanced Ovarian Cancer (AOC), 3. Syneos Health Medical Affairs provides life sciences companies with the depth and breadth of medical affairs expertise needed to optimize product development. Single-agent Belantamab Mafodotin for RRMM: Analysis of the Lyophilized Presentation Cohort from the Pivotal DREAMM-2 Study [Poster not available for viewing due to copyright restrictions], 9. 4. Rothnie KJ, Bancroft T, Bogart M, et al. Preliminary Results from the PRIMA Trial, 2. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Patient-Reported Experiences During and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study, 3. 2018;9:947. Explore Evaluation of immune phenotypes and gene expression profiles in tumors from patients treated with bintrafusp alfa, 4. O?Connor BP, Raman VS, Erikson LD, et al. Tai Y-T, Mayes PA, Acharya C, et al. You may also report suspected adverse events to the Food and Drug Administration (FDA) directly at 1-800-FDA-1088 or www.fda.gov/MedWatch. 2017;31(2):101-1261. Treatment Patterns and Disease Burden of Triple Therapy in Asthma. 5. It is being investigated as monotherapy and in combination with other anticancer agents in various malignancies. POSTER: Phase 2 platform trial of anti-T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) GSK?859A/EOS-448 plus anti-programmed death-1 (PD-1) dostarlimab in patients with non-small cell lung cancer (NSCLC), June 9-12, 2022 | Vienna, Austria | Virtual, 2. In continuation of Cerevel's commitment to boundarypushing and evolving science, this website will be continuously updated with emerging data that allows for providers to make informed decisions and . Medical Affairs will be a strategic leader at the center of clinical development and commercialization efforts, addressing unmet patient, payer, policymaker, and provider needs that advance clinical practice and improve patient outcomes. DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 2. Goodall E, Wood R, Numbere B, et al. A phase 2/3, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer (TiP), 13. Goodall E, Wood R, Numbere B, et al. Causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England. Poster No. Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is involved in driving necroptosis, a proinflammatory form of cell death that may promote metastasis and suppress T-cell?driven antitumor immunity. Use of and access to this site are subject to POSTER: The correlation between PFS and OS in Patient with Ovarian Cancer after Debulking Surgery, 4. If you are an Busse W, Chupp G, Stanaland M, et al. Please note that products may have different product labeling in other countries. DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Pomalidomide and Dexamethasone (B-Pd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 10. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. 6. 1. ?Trap?/Anti-PD-L1 Fusion Protein, Belantamab Mafodotin - Anti-BCMA Immunoconjugate, PRMT5 Inhibitor (GSK3326595) and Type I PRMT Inhibitor (GSK3368715). ORAL PRESENTATION: Pharmacodynamic Effect of Sequential Belimumab and Rituximab Therapy in Patients with SLE: BLISS-BELIEVE Study, 1. Association between TGF-? Dyck L, Mills KHG. GSK3326595, a selective inhibitor of PRMT5, is being investigated as a monotherapy in solid tumors and in combination with other therapies in various hematologic malignancies. Impact of mepolizumab in patients with life-threatening asthma. Helping the brand team in formulating scientific strategy. 2. Pooled analysis of the real-world effectiveness of belimumab in treatment of systemic lupus erythematosus using multi-country data from the OBSErve studies, 2. and PD-L1 pathways. Poster No. Silver J, Bogart M, Molfino N, et al. Mepolizumab Reduces Exacerbations and Improves Health-Related Quality of Life in Patients With Severe Asthma and Nasal Polyps, Sinusitis, or Allergic Rhinitis. Real-World Average Dose of PARP Inhibitors Used as Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer, 1. POSTER: RSVPreF3 OA Candidate Vaccine Efficacy Presentation. Encore: DREAMM-1: Patient Perspectives From the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM) [Publication only], 4.
Solid Right Angled Triangle In Python Assignment Expert, Spinal Cord Stimulator Surgery Video, Landa Hot Water Pressure Washer For Sale, Jazz Concert Copenhagen, Aws Amplify Without Backend,